CMS subtype 1 tumors display a higher percentage of MSI (74%) and CIMP (67%); high BRAF (42%) and lower KRAS (23%) gene mutation status; low somatic copy number alteration (SCNA), immune infiltration, and activation; and worse prognosis, representing 14% of total CRC [6,7]. The gene discussed is KRAS; the disease is colorectal carcinoma.